All In Biotech

Drug Trial Radar · NCT01757184

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

A Multicenter, Randomized, Placebo-controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency

Last checked: Nov 20, 2026Latest source record: Dec 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

66

Actual

Start

Jan 22, 2013

Primary completion

May 30, 2014

Study completion Dec 11, 2018

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study evaluated the efficacy and safety of 1 milligram/kilogram (mg/kg) intravenous (IV) infusions of SBC-102 (sebelipase alfa) administered every other week (qow) in participants with late onset lysosomal acid lipase deficiency (LAL-D) (cholesteryl ester storage disease \[CESD\]). Late-onset LAL-D is an underappreciated cause of cirrhosis, liver failure and dyslipidemia. There is currently no standard treatment for LAL-D other than supportive care. Enzyme replacement therapy may be a potential new treatment option for LAL-D participants.

Conditions

  • Lysosomal Acid Lipase Deficiency

Interventions

  • Sebelipase AlfaDrug

    IV infusions of sebelipase alfa

  • PlaceboDrug

    IV infusions of matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Of Participants Achieving Alanine Aminotransferase NormalizationTime frame: Double-blind Period: Baseline to the end of the Double-blind Period (Week 20). Open-label Period: Baseline to the last Open-label assessment (up to Week 256)

Locations

40 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    Palo Alto, California

  • Site not named

    San Francisco, California

  • Site not named

    Wilmington, Delaware

  • Site not named

    Chicago, Illinois

  • Site not named

    Boston, Massachusetts

  • Site not named

    Buffalo, New York

  • Site not named

    Manhasset, New York

  • Site not named

    New York, New York

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Córdoba, Argentina

  • Site not named

    Brisbane, Australia

  • Site not named

    New Lambton, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Perth, Australia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Paris, France

  • Site not named

    Vandœuvre-lès-Nancy, France

  • Site not named

    Freiburg im Breisgau, Germany

  • Site not named

    Mainz, Germany

  • Site not named

    Munich, Germany

  • Site not named

    Bergamo, Italy

  • Site not named

    Genoa, Italy

  • Site not named

    Padova, Italy

  • Site not named

    Tokyo, Japan

  • Site not named

    Tottori, Japan

  • Site not named

    Mexico City, Mexico

  • Site not named

    Warsaw, Poland

  • Site not named

    Moscow, Russia

  • Site not named

    Elche, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Oviedo, Spain

  • Site not named

    Ankara, Turkey (Türkiye)

  • Site not named

    Izmir, Turkey (Türkiye)

  • Site not named

    Cambridge, United Kingdom

  • Site not named

    London, United Kingdom

  • Site not named

    Plymouth, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.